摘要
目标:流行病学数据表明非甾体类抗炎药(NSAIDs)可以预防阿尔茨海默病(AD)。不幸的是,最近的试验未能提供令人信服的神经保护证据。关于为什么NSAIDs有效性尚不确定的讨论正在进行中。可能的解释包括在患者出现AD或认知功能下降症状之前应提供NSAIDs和其他可能的疾病缓解药物。另外,用于神经保护的NSAID目标还不清楚。已提出COX依赖性和独立机制,包括裂解淀粉样蛋白前体蛋白(APP)并产生淀粉样蛋白β肽(Aβ)的γ-分泌酶。 方法:我们已经提出了基于抑制线粒体Ca 2+超载的NSAID的神经保护机制。 Aβ寡聚体促进Ca2 +内流和线粒体Ca2 +超载导致神经元细胞死亡。包括布洛芬,舒林酸,吲哚美辛和Rflurbiprofen在内的几种非特异性NSAIDs在低μM范围内使线粒体去极化,并防止由Aβ寡聚体和/或N-甲基-D-天冬氨酸(NMDA)诱导的线粒体Ca2 +超载。然而,在较高的浓度下,NSAIDs可能会破坏导致细胞死亡的线粒体潜能(ΔΨ)。 结果:因此,这种机制可能解释低浓度的神经保护作用和更大剂量的损伤,从而为有希望的试验的失败提供线索。对于将来的试验,应考虑降低NSAID浓度和/或具有较大动态范围的替代化合物以提供针对AD的神经保护的确切证据
关键词: 阿尔茨海默氏病,非甾体抗炎药,钙,线粒体,淀粉样蛋白β寡聚体,N-甲基-D-天冬氨酸。
Current Alzheimer Research
Title:Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake
Volume: 15 Issue: 6
关键词: 阿尔茨海默氏病,非甾体抗炎药,钙,线粒体,淀粉样蛋白β寡聚体,N-甲基-D-天冬氨酸。
摘要: Objectives: Epidemiological data suggest that non-steroidal anti-inflammatory drugs (NSAIDs) may protect against Alzheimer's disease (AD). Unfortunately, recent trials have failed in providing compelling evidence of neuroprotection. Discussion as to why NSAIDs effectivity is uncertain is ongoing. Possible explanations include the view that NSAIDs and other possible disease-modifying drugs should be provided before the patients develop symptoms of AD or cognitive decline. In addition, NSAID targets for neuroprotection are unclear. Both COX-dependent and independent mechanisms have been proposed, including γ-secretase that cleaves the amyloid precursor protein (APP) and yields amyloid β peptide (Aβ).
Methods: We have proposed a neuroprotection mechanism for NSAIDs based on inhibition of mitochondrial Ca2+ overload. Aβ oligomers promote Ca2+ influx and mitochondrial Ca2+ overload leading to neuron cell death. Several non-specific NSAIDs including ibuprofen, sulindac, indomethacin and Rflurbiprofen depolarize mitochondria in the low µM range and prevent mitochondrial Ca2+ overload induced by Aβ oligomers and/or N-methyl-D-aspartate (NMDA). However, at larger concentrations, NSAIDs may collapse mitochondrial potential (ΔΨ) leading to cell death.
Results: Accordingly, this mechanism may explain neuroprotection at low concentrations and damage at larger doses, thus providing clues on the failure of promising trials. Perhaps lower NSAID concentrations and/or alternative compounds with larger dynamic ranges should be considered for future trials to provide definitive evidence of neuroprotection against AD.
Export Options
About this article
Cite this article as:
Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake, Current Alzheimer Research 2018; 15 (6) . https://dx.doi.org/10.2174/1567205015666171227154016
DOI https://dx.doi.org/10.2174/1567205015666171227154016 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genotoxicity in Alzheimers Disease: Role of Amyloid
Current Alzheimer Research Oxidative Damage Impact on Aging and Age-Related Diseases: Drug Targeting of Telomere Attrition and Dynamic Telomerase Activity Flirting with Imidazole-Containing Dipeptides
Recent Patents on Drug Delivery & Formulation Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Phytochemical Informatics and Virtual Screening of Herbs Used in Chinese Medicine
Current Pharmaceutical Design Antiatherosclerotic and Cardioprotective Effects of Time-Released Garlic Powder Pills
Current Pharmaceutical Design Tau in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research Formulation and Assessment of In Vivo Anti-Inflammatory Potential of Omega-3-Fatty Acid Loaded Self Emulsifying Nanoemulsion
Current Nanomedicine Immunotherapy in a Natural Model of Aβ Pathogenesis: The Aging Beagle
CNS & Neurological Disorders - Drug Targets Characterization of Myelin Pathology in the Hippocampal Complex of a Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design Oxidative Stress in Alzheimer Patients in Different Stages of the Disease
Current Medicinal Chemistry Curcumin Prevents Brain Damage and Cognitive Dysfunction During Ischemic-reperfusion Through the Regulation of miR-7-5p
Current Neurovascular Research EEG Upper/Low Alpha Frequency Power Ratio and the Impulsive Disorders Network in Subjects with Mild Cognitive Impairment.
Current Alzheimer Research DNA Double Strand Breaks: A Common Theme in Neurodegenerative Diseases
Current Alzheimer Research Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases
Current Vascular Pharmacology Recent Advances in the Applications of SAMP/RAMP as Chiral Auxiliaries in Asymmetric Synthesis
Current Organic Synthesis The Effects of Lipid-Regulating Therapy on Haemostatic Parameters
Current Pharmaceutical Design